Doyle Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
CI
Doyle Wealth Management's XBI Position: Q3 2019 in Review
Doyle Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2019, closing a stake of 130 shares — an estimated $11K sold.
Doyle Wealth Management first reported a position in XBI in Q4 2018 and held it in 2 quarters. The position peaked at $11K in Q2 2019. 406 funds tracked by Wall St. Rank hold XBI as of Q3 2019.
- Doyle Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2019 after selling out during the quarter.
- Doyle Wealth Management sold 130 State Street SPDR S&P Biotech ETF shares in Q3 2019, an estimated $11K.
- Doyle Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 2 quarters.
- Doyle Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $11K in Q2 2019.
- 406 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2019.
Based on Doyle Wealth Management's 13F filing for Q3 2019, filed 5 Nov 2019.